USPTO Patent Applications - Therapeutics (A61P)

Immune Cells Target EpCAM for Tumor Treatment

The USPTO has published a patent application (US20260083843A1) from SUZHOU IMMUNOHEAD BIOTECHNOLOGY CO., LTD. The application details the use of immune cells that target EpCAM for the prevention or treatment of metastatic tumors expressing EpCAM.

Cellicure, Inc. Patent Application for Engineered Immune Cells

The USPTO has published a patent application (US20260083845A1) filed by Cellicure, Inc. on September 22, 2023. The application details engineered immune cells, specifically chimeric antigen receptors (CARs) for enhanced killing activities, primarily targeting cancer treatment.

USPTO Patent Application: Polynucleotides Targeting NR4A3

The USPTO has published a patent application (US20260083846A1) filed by Lyell Immunopharma, Inc. The application describes polynucleotides designed to target the NR4A3 gene and their potential use in treating diseases, including cancer. The patent is scheduled to be published on March 26, 2026.

Patent Application: T-cell receptors target mutant RAS for cancer treatment

The USPTO has published patent application US20260083847A1 concerning T-cell receptors and compositions for treating cancer associated with mutant RAS. The application details methods and compositions involving T-cell receptors that bind to specific mutant RAS peptide fragments in the context of specific HLA types.

CAR T-cell therapy combined with BTK inhibitors for cancer

The USPTO has published a new patent application (US20260083848A1) detailing a combination therapy for cancer treatment. The application describes the use of CAR T-cell therapy with BTK inhibitors for treating hematological malignancies. This represents a new disclosure in the field of cancer therapeutics.

Modified T-Cells for Bladder Cancer Treatment Application

The USPTO has published a patent application (US20260083849A1) detailing a method for treating bladder cancer using modified immunoresponsive cells. The application was filed on September 7, 2023, and is related to therapeutic applications in oncology.

Patent for Radiation Dose Enhancement and Tumor Delineation

The USPTO has published a new patent application (US20260083850A1) for compounds, compositions, and methods related to radiation dose enhancement and tumor delineation. The application, assigned to the University of Connecticut, focuses on using barium nanoparticles for improved radiation therapy and tumor identification.

Proteoglycan Mimetics for Wound Healing and Angiogenesis

The USPTO has published a new patent application, US20260083852A1, detailing proteoglycan mimetics for enhanced wound healing and angiogenesis. The application describes compounds designed to support tissue regeneration and promote vascular repair, potentially limiting systemic exposure to VEGF activity.

USPTO Patent for Therapeutic Compounds Treating Cancer

The USPTO has published patent application US20260085059A1 for therapeutic compounds and methods of use in treating cancer. The patent was assigned to Servier Pharmaceuticals LLC and lists Samuel V. Agresta et al. as inventors. The application was filed on May 7, 2025.

Chemical Compound with Triazine Group and Production Method

The USPTO has published a patent application (US20260085087A1) for a chemical compound comprising a triazine group and its production method. The application relates to novel nucleotides and oligonucleotides with modified phosphate groups, potentially useful in diagnostics, gene therapy, and treating bacterial and viral diseases, including COVID-19.

Antimicrobial Compositions Patent Application

The USPTO has published a patent application (US20260083126A1) for antimicrobial compositions containing organosulfur compounds. The application, filed on September 8, 2023, describes compounds useful for treating microbial infections and for cleaning, disinfecting, or agricultural use.

Meloxicam Pharmaceutical Composition and Application

The USPTO has published a patent application (US20260083748A1) for a pharmaceutical composition containing meloxicam, a composite solvent, and an acidic pH regulator. The assignee is Beijing Tide Pharmaceutical Co., Ltd. This application details a preparation method and its application, focusing on a formulation that avoids organic solvents for increased safety and reduced environmental impact.

Patent application for Dichrostachys glomerata health and wellness benefits

Patent application for Dichrostachys glomerata health and wellness benefits

Patent Application for Reducing Food Intake Using Plants

The USPTO has published a new patent application (US20260083800A1) detailing methods and compositions using Dichrostachys glomerata or Cissus quadrangularis to reduce food intake or appetite in mammals. The application was filed on September 26, 2024, by inventors Shil Kothari and Julius Enyoug Oben.

Patent Application for Reducing Visceral Fat Using Plants

The USPTO has published a new patent application (US20260083801A1) detailing methods and compositions for reducing visceral fat in mammals using plants like Dichrostachys glomerata or Cissus quadrangularis. The application was filed on September 26, 2024, and is expected to be published on March 26, 2026.

Patent Application: Methods for Reducing Blood Lipids Using Plants and Spices

The USPTO has published a new patent application (US20260083802A1) detailing methods and compositions for reducing blood lipids using plants and spices, specifically Dichrostachys glomerata or Cissus quadrangularis. The application was filed on September 26, 2024.

Patent Application for Reducing Blood Glucose with Plants

The USPTO has published a new patent application (US20260083803A1) detailing methods and compositions for reducing fasting blood glucose in mammals using plants like Dichrostachys glomerata or Cissus quadrangularis. The application was filed on September 26, 2024, and is expected to be published on March 26, 2026.

Patent Application: Reducing DPP-4 Activity Using Plants

The USPTO has published a new patent application (US20260083804A1) detailing methods and compositions for reducing DPP-4 activity using plants like Dichrostachys glomerata or Cissus quadrangularis. The application, filed on September 26, 2024, aims to provide health benefits such as increased GLP-1 levels and reduced visceral fat.

Phytogenic Composition for Animal Skeletal Muscle Growth

The USPTO has published a patent application (US20260083805A1) detailing a phytogenic composition comprising Glycyrrhiza uralensis extract for promoting skeletal muscle growth in animals. This application outlines its use as a feed additive for agricultural applications.

USPTO Patent Application for Anti-CD38 Antibodies

The USPTO has published a patent application (US20260078199A1) for anti-CD38 antibodies, therapeutics, and diagnostics. The application, filed on July 14, 2025, details methods for treating autoimmune diseases and diagnostic assays.

USPTO Patent Application: Systems for Targeting Cancer Cells

The USPTO has published a new patent application, US20260078200A1, detailing systems and methods for targeting cancer cells using genetically modified immune cells. The application describes novel polypeptides and their use in killing target cancer cells.

Anti-PTK7 Antibody Patent Application

The USPTO has published a patent application (US20260078201A1) for an anti-PTK7 antibody. The antibody is described as inhibiting angiogenesis, tumor growth, and cancer, with potential therapeutic applications for angiogenesis-related diseases and PTK7-positive cancers.

Carboxyalkyl Chitosan Patent Application

The USPTO has published a patent application (US20260078203A1) for a carboxyalkyl chitosan. The application details compositions, manufacturing processes, and therapeutic applications in areas such as rheumatology, ophthalmology, and dermatology. The filing date was November 26, 2025.